ArticleExperimental dermatology2026
The Secretome of Bullous Pemphigoid IgG-Treated Keratinocytes Induces a Pro-Inflammatory Eosinophil Response.
Article in Experimental dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Bullous pemphigoid (BP) is an autoimmune blistering disease whereby the cutaneous antigens BP180 and BP230 are targeted by autoantibodies. Skin lesions in BP are characterized by an abundance of eosinophils. We recently demonstrated that the treatment of keratinocytes with antibodies from patients with BP induces a robust inflammatory response with release of numerous cytokines, chemokines, complement factors, and proteases. We thus questioned whether this keratinocyte inflammatory response was capable of directly inducing an inflammatory response in eosinophils. We therefore treated human eosinophils with conditioned media from keratinocytes treated with IgG from patients with BP (BP-IgG), or healthy controls (control-IgG) with or without supplemental IL-5. Flow cytometry revealed upregulation of CD107a/CD107b, markers of degranulation, on eosinophils treated with supernatants from BP-IgG relative to control-IgG treated keratinocytes. A decrease in CCR3 and CD101 was also identified. Functional activity of eosinophils was confirmed by performing a multiplex immunoassay on eosinophil supernatants. This revealed significant upregulation IL-6, IL-8, LIF, TGFα, MCP-4, MMP-9, and MMP-10. Supplemental IL-5 did not appear to significantly influence these responses. Our data demonstrate that the inflammatory activation of keratinocytes by BP-IgG affects eosinophils, driving phenotypic changes consistent with degranulation, as well as a pro-inflammatory and proteolytic response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.